Breckenridge Pharmaceutical
This article was originally published in The Tan Sheet
Executive Summary
Forms subsidiary to market OTC versions of prescription drugs. Breckenridge will launch its first OTC product, Prodium (phenazopyridine hydrochloride 95 mg) for the treatment of pain and discomfort due to urinary tract infections beginning in October. Prodium will compete with the leading brand, PolyMedica's Azo-Standard, for a share of the $60 mil. OTC phenazopyridine HCl market. The product will be available in 30- and 12-tablet containers. Breckenridge plans to support the product with medical and consumer marketing as well as education programs targeted to physicians, pharmacists and consumers
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning